-
Become Medical and MGI reached a cooperation to develop the next-generation automated experimental platform for assisted reproduction
Time of Update: 2021-07-13
Beikang Medical plans to invest 430 million yuan in the field of assisted reproduction in the next 5 years to build an integrated overall experimental platform solution from detection to storage, to achieve automated gene sequencing and automated ultra-low temperature storage at the embryonic single-cell level, and complete PGT-M and PGT -SR clinical registration of two test kits, construction of a three-category medical device registration product pipeline and automated laboratory platform solutions covering the entire reproductive cycle .
-
The value of the third-party commercial platform is prominent!
Time of Update: 2021-07-13
Zhou Hong, President of Roche Pharmaceuticals China, said that the cooperation with Baiyang Pharmaceuticals this time will allow both parties to give full play to their respective advantages to allow original drugs such as Xeloda® and Tarceva® to continue to release the value and help more Chinese cancer patients .
-
Xinlitai independent director He Suying resigns after term of office expires
Time of Update: 2021-07-13
According to the "Guiding Opinions on Establishing an Independent Director System in Listed Companies", "Independent directors shall not be re-elected for more than six years" and other related regulations, He Suying's term of office is about to expire, and he applied for resignation from Xinlitai as an independent director, and at the same time resigned from the audit committee of the board of directors.
-
Chairman Zheng Xiangling was honored as "2020 China's Top Ten Ingenuity Figures" and "2020 China Outstanding Charity Figures"
Time of Update: 2021-07-13
Zheng Xiangling also actively mobilized members from all walks of life to carry out donations and materials to fight the new crown pneumonia epidemic, and donated nearly 800,000 masks and 10 negative pressure ambulances .
-
Tianjing Bio and ABL Bio announce that TJ-CD4B/ABL111 has been approved by the FDA for Phase 1 clinical trials
Time of Update: 2021-07-13
, We will continue to work with Tianjing Bio to accelerate the progress of clinical research and development, and strive to bring new treatment options to patients with advanced and metastatic solid tumors as soon as possible .
-
The logic behind the thousands of casualties!
Time of Update: 2021-07-13
After 12 years of suspension of production of the drugs involved, pharmaceutical companies finally ushered in tens of millions of fines .
These doctors recommend that pharmaceutical companies conduct more trials before they can put the drug on the market, otherwise they refuse to prescribe the drug .
-
Henlius Announces 2020 Annual Results
Time of Update: 2021-07-13
Excellent commercialization: A variety of products are launched to welcome the intensive harvest period, and the comprehensive commercialization capabilities deepen the value As of the end of 2020, Henlius has successfully marketed products in China and the EU including: China's first biosimilar drug Hanlikang® (rituximab), China's first self-developed Sino-European dual-batch monoclonal antibody drug Hanquyou ® (Trastuzumab, EU trade name: Zercepac®) and the company's first product Handayuan® (adalimumab) for the treatment of autoimmune diseases .
-
Tarsus Pharmaceuticals and Liantuo Biotech announced the establishment of a strategic cooperation to jointly develop and commercialize TP-03 for the treatment of Demodex blepharitis and meibomian gland dysfunction in Greater China.
Time of Update: 2021-07-13
" "It is estimated that there are more than 100 million patients with Demodex blepharitis and meibomian gland dysfunction in China, and at the same time, four phase 2 clinical trials of TP-03 continue to produce convincing data .
-
WuXi AppTec achieves strong growth in 2020 performance
Time of Update: 2021-07-13
, a company capable of providing comprehensive and integrated new drug R&D and production services and technology platform for the global biopharmaceutical industry, released its 2020 annual report .
-
Jacos Pharmaceuticals releases 2020 full-year results, full-year revenue of 486 million yuan
Time of Update: 2021-07-13
As a research and development biotechnology company in the clinical stage, GACOS has made a number of progress in its research products in 2020, and the clinical research of the core project SHP2 inhibitor has entered the second phase .
-
Shengxiang Biological Supervisor Chen Bing resigns
Time of Update: 2021-07-13
In addition, on March 26, Shengxiang Biological held the second meeting of the first board of supervisors in 2021, and reviewed and passed the "Proposal on Replacement of Supervisors by Shengxiang Biological Technology Co.
-
Merck cooperates with SignalChem
Time of Update: 2021-07-13
On March 26, according to foreign media reports, SignalChem Lifesciences, a clinical-stage company that develops new tumor-targeted therapies, announced a partnership with Merck and Merck through a subsidiary to evaluate the selective AXL inhibitor SLC-391 developed by SignalChem and Merck’s anti-PD-1 Therapeutic effect of KEYTRUDA® (pembrolizumab) combination in patients with advanced non-small cell lung cancer (NSCLC) .
-
Anti-LAG-3 antibody Relatlimab combined with Odivo bring benefits to melanoma patients
Time of Update: 2021-07-13
March 25, 2021, Bristol-Myers Squibb (NYSE: BMY) announced (CA224-047) preliminary results of a Phase 2/3 clinical study RELATIVITY-047, which was designed to evaluate and Ou Diwo ® (Wu Li You satisfied mAb) monotherapy compared with the fixed-dose combination of anti-LAG-3 antibody and Ou Diwo relatlimab ® treatment for previously untreated, unresectable or metastatic melanoma patients .
-
Shanghai Stock Exchange terminates Tianguangshi Technology Innovation Board IPO
Time of Update: 2021-07-13
In accordance with the relevant provisions of Article 67 of the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Issuance and Listing Review Rules", the Exchange has decided to terminate the review of Tianguangshi's initial public offering and listing on the Science and Technology Innovation Board .
-
The first Chinese patient was enrolled in the clinical study of the global registration of a new class 1 new drug for ovarian cancer in Laikai Medicine
Time of Update: 2021-07-13
announced that it has developed a new class 1 drug Afuresertib (LAE002) for the treatment of platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer (PROC), Global multi-center Phase II clinical trials have been fully launched in China and the United States .
-
2021 China Cancer Health Management Conference and the Fifth Breast Cancer Management Chief Expert Forum held
Time of Update: 2021-07-13
" Academician He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, pointed out: "To achieve the goal of a 15% increase in the overall cancer survival rate in five years in the'Healthy China 2030' plan is not only necessary Promote the implementation of a patient-centered'all-round' cross-field health management strategy.
-
China's first self-innovative microsphere preparation, Rexinto, was launched
Time of Update: 2021-07-13
As China's first innovative microsphere preparation with independent intellectual property rights and global registration, it is also the first domestically developed second-generation long-acting antipsychotic injection, Rexinto® has been marketed for about 10 million people with schizophrenia in China The reintegration of patients with the disease brings new hope .
-
GenScript Biotechnology Announces 2020 Annual Results
Time of Update: 2021-07-13
This is mainly due to: (i) investing in new coronary pneumonia-related projects and other challenging new research and development projects, which have greatly improved our market competitiveness and production efficiency; (ii) clinical trial expenses and preclinical research costs (especially cell Therapeutics segment) increased; and (iii) R&D staff's remuneration package (including share-based payments) increased .
-
BeiGene announces the appointment of Wang Aijun as its new chief financial officer
Time of Update: 2021-07-13
Aijun Wang said: “I am honored to be the Chief Financial Officer of BeiGene, and together with the company to revolutionize the biotechnology industry by creating influential, affordable and accessible drugs for more patients around the world .
-
Development Pharmaceutical Announces 2020 Annual Results, Procruamide Treatment of New Crown Commercialization Is Coming
Time of Update: 2021-07-13
On March 26, 2021, Kaifeng Pharmaceutical Co. , Ltd. , an innovative drug research and development company focusing on the androgen receptor (AR) and tumor fields as its core, announced its recent bu
